Effects of Metyrapone in Patients With Hypercortisolism
NCT ID: NCT05255900
Last Updated: 2025-09-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Total Enrollment
20 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-04-28
Study Completion Date
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aims of the present study are to evaluate in patients with mild hypercortisolism the effect of metyrapone treatment on glycometabolic control, blood pressure, thrombotic risk parameters, lipid profile, bone turnover markers, mental health and cortisol circadian rhythm.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
NCT07138274
Mild Autonomous Cortisol Secretion (MACS)
Autonomous Cortisol Secretion (ACS)
NOT_YET_RECRUITING
PHASE2
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
NCT00426608
Depressive Disorder and Anxiety Disorders
COMPLETED
PHASE1
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162
Hypertension
Hypercortisolemia
Cushing Syndrome
NOT_YET_RECRUITING
PHASE4
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
NCT06635629
Cushing Syndrome
RECRUITING
PHASE2
Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake
NCT06556277
Glucocorticoids
Overweight and Obesity
Overeating
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This open prospective observational study will include patients with mild hypercortisolism of both adrenal and pituitary origin not candidate for surgery. Patients taking metyrapone since less than a week will be followed up for 24 weeks. During this period of time, patients will be re-evaluated as far as blood pressure control, glycometabolic control, thrombotic risk parameters, lipid profile, bone turnover markers and cortisol circadian rhythm is concerned.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypercortisolism
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
metyrapone treatment
hypercortisolemic patients taking metyrapone since less than a week (usually 250 mg/day, maximum dose 6000 mg/day)
Metyrapone Capsules
Intervention Type
DRUG
Exposure to 24 weeks of treatment with metyrapone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metyrapone Capsules
Exposure to 24 weeks of treatment with metyrapone
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with mild Cushing's Syndrome not candidate for surgery
* Current therapy with metyrapone since less than 1 week
* Cortisol levels at 08:00 after 1 mg-overnight dexamethasone suppression test (1mgDST) \>1.8 μg/dL
* Confirmed with 2 mg two days dexamethasone suppression test (2mgx2dDST)
* Presence of at least one out of the following conditions: type 2 diabetes mellitus, impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), arterial hypertension, bone mineral density (BMD) Z-score \< -2.0 and/or fragility fracture at any skeletal site
* Stable anti-hypertensive therapies and blood pressure (BP) levels in the month before enrolment
* Stable anti-diabetic therapies and glycometabolic control during the month before enrolment
* Stable body weight during the month before enrolment
* Current therapy with metyrapone since less than 1 week
* Cortisol levels at 08:00 after 1 mg-overnight dexamethasone suppression test (1mgDST) \>1.8 μg/dL
* Confirmed with 2 mg two days dexamethasone suppression test (2mgx2dDST)
* Presence of at least one out of the following conditions: type 2 diabetes mellitus, impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), arterial hypertension, bone mineral density (BMD) Z-score \< -2.0 and/or fragility fracture at any skeletal site
* Stable anti-hypertensive therapies and blood pressure (BP) levels in the month before enrolment
* Stable anti-diabetic therapies and glycometabolic control during the month before enrolment
* Stable body weight during the month before enrolment
Exclusion Criteria
* Signs and/or symptoms of overt hypercortisolism (striae rubrae, moon facies, easy bruising, buffalo hump, hypertrichosis)
* Malignant hypertension and/or BP \<200/120 mmHg
* Severe hyperglycemia (i.e. FG \>350 mg/dL)
* Urinary free cortisol (UFC) higher than 1.5 fold the upper normal range
* Presence of pheochromocytoma or primary hyperaldosteronism
* Possible adrenal metastases or radiological features suggestive for adrenal malignancy (i.e. not homogeneous pattern, necrosis, calcifications, irregular margins, local invasion and high density at computed tomography)
* Congenital adrenal hyperplasia
* Intake of drugs influencing cortisol metabolism and/or secretion
* Women in child-bearing age
* Patients with body mass index (BMI) \>35 kg/m2
* Malignant hypertension and/or BP \<200/120 mmHg
* Severe hyperglycemia (i.e. FG \>350 mg/dL)
* Urinary free cortisol (UFC) higher than 1.5 fold the upper normal range
* Presence of pheochromocytoma or primary hyperaldosteronism
* Possible adrenal metastases or radiological features suggestive for adrenal malignancy (i.e. not homogeneous pattern, necrosis, calcifications, irregular margins, local invasion and high density at computed tomography)
* Congenital adrenal hyperplasia
* Intake of drugs influencing cortisol metabolism and/or secretion
* Women in child-bearing age
* Patients with body mass index (BMI) \>35 kg/m2
Minimum Eligible Age
18 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HRA Pharma
INDUSTRY
Sponsor Role
collaborator
Istituto Auxologico Italiano
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chiodini Chiodini, Professor
Role: PRINCIPAL_INVESTIGATOR
Istituto Auxologico Italiano IRCCS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Auxologico Italiano
Milan, , Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
References
Explore related publications, articles, or registry entries linked to this study.
Zavatta G, Di Dalmazi G. Recent Advances on Subclinical Hypercortisolism. Endocrinol Metab Clin North Am. 2018 Jun;47(2):375-383. doi: 10.1016/j.ecl.2018.01.003. Epub 2018 Apr 9.
Reference Type
BACKGROUND
Chiodini I, Morelli V. Subclinical Hypercortisolism: How to Deal with It? Front Horm Res. 2016;46:28-38. doi: 10.1159/000443862. Epub 2016 May 17.
Reference Type
BACKGROUND
Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011 May;96(5):1223-36. doi: 10.1210/jc.2010-2722. Epub 2011 Mar 2.
Reference Type
BACKGROUND
Morelli V, Arosio M, Chiodini I. Cardiovascular mortality in patients with subclinical Cushing. Ann Endocrinol (Paris). 2018 Jun;79(3):149-152. doi: 10.1016/j.ando.2018.03.005. Epub 2018 Mar 30.
Reference Type
BACKGROUND
Patrova J, Kjellman M, Wahrenberg H, Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. Endocrine. 2017 Nov;58(2):267-275. doi: 10.1007/s12020-017-1400-8. Epub 2017 Sep 8.
Reference Type
BACKGROUND
Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, Mosconi C, Golfieri R, Paccapelo A, Pagotto U, Pasquali R. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014 May;2(5):396-405. doi: 10.1016/S2213-8587(13)70211-0. Epub 2014 Jan 29.
Reference Type
BACKGROUND
Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab. 2014 Dec;99(12):4462-70. doi: 10.1210/jc.2014-3007.
Reference Type
BACKGROUND
Morelli V, Reimondo G, Giordano R, Della Casa S, Policola C, Palmieri S, Salcuni AS, Dolci A, Mendola M, Arosio M, Ambrosi B, Scillitani A, Ghigo E, Beck-Peccoz P, Terzolo M, Chiodini I. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab. 2014 Mar;99(3):827-34. doi: 10.1210/jc.2013-3527. Epub 2014 Jan 1.
Reference Type
BACKGROUND
Park J, De Luca A, Dutton H, Malcolm JC, Doyle MA. Cardiovascular Outcomes in Autonomous Cortisol Secretion and Nonfunctioning Adrenal Adenoma: A Systematic Review. J Endocr Soc. 2019 Mar 25;3(5):996-1008. doi: 10.1210/js.2019-00090. eCollection 2019 May 1.
Reference Type
BACKGROUND
Chiodini I, Vainicher CE, Morelli V, Palmieri S, Cairoli E, Salcuni AS, Copetti M, Scillitani A. MECHANISMS IN ENDOCRINOLOGY: Endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol. 2016 Dec;175(6):R265-R282. doi: 10.1530/EJE-16-0289. Epub 2016 Jul 13.
Reference Type
BACKGROUND
Morelli V, Ghielmetti A, Caldiroli A, Grassi S, Siri FM, Caletti E, Mucci F, Aresta C, Passeri E, Pugliese F, Di Giorgio A, Corbetta S, Scillitani A, Arosio M, Buoli M, Chiodini I. Mental Health in Patients With Adrenal Incidentalomas: Is There a Relation With Different Degrees of Cortisol Secretion? J Clin Endocrinol Metab. 2021 Jan 1;106(1):e130-e139. doi: 10.1210/clinem/dgaa695.
Reference Type
BACKGROUND
Li D, Kaur RJ, Zhang CD, Ebbehoj A, Singh S, Atkinson EJ, Achenbach SJ, Rocca W, Khosla S, Bancos I. Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study. Eur J Endocrinol. 2021 Apr;184(4):597-606. doi: 10.1530/EJE-20-1396.
Reference Type
BACKGROUND
Terzolo M, Pia A, Reimondo G. Subclinical Cushing's syndrome: definition and management. Clin Endocrinol (Oxf). 2012 Jan;76(1):12-8. doi: 10.1111/j.1365-2265.2011.04253.x.
Reference Type
BACKGROUND
Vassiliadi DA, Partsalaki E, Tsagarakis S. Approach to patients with bilateral adrenal incidentalomas. Curr Opin Endocrinol Diabetes Obes. 2020 Jun;27(3):125-131. doi: 10.1097/MED.0000000000000536.
Reference Type
BACKGROUND
Vassiliadi DA, Ntali G, Vicha E, Tsagarakis S. High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin Endocrinol (Oxf). 2011 Apr;74(4):438-44. doi: 10.1111/j.1365-2265.2010.03963.x.
Reference Type
BACKGROUND
Vassilatou E, Vryonidou A, Ioannidis D, Paschou SA, Panagou M, Tzavara I. Bilateral adrenal incidentalomas differ from unilateral adrenal incidentalomas in subclinical cortisol hypersecretion but not in potential clinical implications. Eur J Endocrinol. 2014 Jul;171(1):37-45. doi: 10.1530/EJE-13-0848. Epub 2014 Apr 17.
Reference Type
BACKGROUND
Pasternak JD, Seib CD, Seiser N, Tyrell JB, Liu C, Cisco RM, Gosnell JE, Shen WT, Suh I, Duh QY. Differences Between Bilateral Adrenal Incidentalomas and Unilateral Lesions. JAMA Surg. 2015 Oct;150(10):974-8. doi: 10.1001/jamasurg.2015.1683.
Reference Type
BACKGROUND
Morelli V, Palmieri S, Salcuni AS, Eller-Vainicher C, Cairoli E, Zhukouskaya V, Scillitani A, Beck-Peccoz P, Chiodini I. Bilateral and unilateral adrenal incidentalomas: biochemical and clinical characteristics. Eur J Endocrinol. 2013 Jan 17;168(2):235-41. doi: 10.1530/EJE-12-0777. Print 2013 Feb.
Reference Type
BACKGROUND
Toini A, Dolci A, Ferrante E, Verrua E, Malchiodi E, Sala E, Lania AG, Chiodini I, Beck-Peccoz P, Arosio M, Spada A, Mantovani G. Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma. Eur J Endocrinol. 2015 Apr;172(4):363-9. doi: 10.1530/EJE-14-0599.
Reference Type
BACKGROUND
Chiodini I, Albani A, Ambrogio AG, Campo M, De Martino MC, Marcelli G, Morelli V, Zampetti B, Colao A, Pivonello R; ABC Group. Six controversial issues on subclinical Cushing's syndrome. Endocrine. 2017 May;56(2):262-266. doi: 10.1007/s12020-016-1017-3. Epub 2016 Jul 12.
Reference Type
BACKGROUND
Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018 Oct 1;179(4):G1-G46. doi: 10.1530/EJE-18-0608.
Reference Type
BACKGROUND
Bancos I, Alahdab F, Crowley RK, Chortis V, Delivanis DA, Erickson D, Natt N, Terzolo M, Arlt W, Young WF Jr, Murad MH. THERAPY OF ENDOCRINE DISEASE: Improvement of cardiovascular risk factors after adrenalectomy in patients with adrenal tumors and subclinical Cushing's syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2016 Dec;175(6):R283-R295. doi: 10.1530/EJE-16-0465. Epub 2016 Jul 22.
Reference Type
BACKGROUND
Salcuni AS, Morelli V, Eller Vainicher C, Palmieri S, Cairoli E, Spada A, Scillitani A, Chiodini I. Adrenalectomy reduces the risk of vertebral fractures in patients with monolateral adrenal incidentalomas and subclinical hypercortisolism. Eur J Endocrinol. 2016 Mar;174(3):261-9. doi: 10.1530/EJE-15-0977. Epub 2015 Dec 2.
Reference Type
BACKGROUND
Papierska L, Cwikla J, Rabijewski M, Glinicki P, Otto M, Kasperlik-Zaluska A. Adrenal (131)I-6beta-iodomethylnorcholesterol scintigraphy in choosing the side for adrenalectomy in bilateral adrenal tumors with subclinical hypercortisolemia. Abdom Imaging. 2015 Oct;40(7):2453-60. doi: 10.1007/s00261-015-0452-6.
Reference Type
BACKGROUND
Albiger NM, Ceccato F, Zilio M, Barbot M, Occhi G, Rizzati S, Fassina A, Mantero F, Boscaro M, Iacobone M, Scaroni C. An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. Clin Endocrinol (Oxf). 2015 Jun;82(6):808-15. doi: 10.1111/cen.12763. Epub 2015 Mar 27.
Reference Type
BACKGROUND
Donadio F, Morelli V, Salcuni AS, Eller-Vainicher C, Carletto M, Castellani M, Dellavedova L, Scillitani A, Beck-Peccoz P, Chiodini I. Role of adrenal gland scintigraphy in patients with subclinical hypercortisolism and incidentally discovered adrenal mass. J Endocrinol Invest. 2009 Jul;32(7):576-80. doi: 10.1007/BF03346511. Epub 2009 Jun 15.
Reference Type
BACKGROUND
Debillon E, Velayoudom-Cephise FL, Salenave S, Caron P, Chaffanjon P, Wagner T, Massoutier M, Lambert B, Benoit M, Young J, Tabarin A, Chabre O. Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab. 2015 Dec;100(12):4417-24. doi: 10.1210/jc.2015-2662. Epub 2015 Oct 9.
Reference Type
BACKGROUND
Giovanelli L, Aresta C, Favero V, Bonomi M, Cangiano B, Eller-Vainicher C, Grassi G, Morelli V, Pugliese F, Falchetti A, Gennari L, Scillitani A, Persani L, Chiodini I. Hidden hypercortisolism: a too frequently neglected clinical condition. J Endocrinol Invest. 2021 Aug;44(8):1581-1596. doi: 10.1007/s40618-020-01484-2. Epub 2021 Jan 4.
Reference Type
BACKGROUND
Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol. 2019 Apr;7(4):300-312. doi: 10.1016/S2213-8587(18)30155-4. Epub 2018 Jul 20.
Reference Type
BACKGROUND
Puglisi S, Perotti P, Barbot M, Cosio P, Scaroni C, Stigliano A, Lardo P, Morelli V, Polledri E, Chiodini I, Reimondo G, Pia A, Terzolo M. Preoperative treatment with metyrapone in patients with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. Endocr Connect. 2018 Nov;7(11):1227-1235. doi: 10.1530/EC-18-0400.
Reference Type
BACKGROUND
Daniel E, Newell-Price JD. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome. Eur J Endocrinol. 2015 Jun;172(6):R263-80. doi: 10.1530/EJE-14-1014. Epub 2015 Jan 30.
Reference Type
BACKGROUND
Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, Chortis V, Cuthbertson DJ, Daousi C, Rajeev SP, Davis J, Cheer K, Drake W, Gunganah K, Grossman A, Gurnell M, Powlson AS, Karavitaki N, Huguet I, Kearney T, Mohit K, Meeran K, Hill N, Rees A, Lansdown AJ, Trainer PJ, Minder AE, Newell-Price J. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. J Clin Endocrinol Metab. 2015 Nov;100(11):4146-54. doi: 10.1210/jc.2015-2616. Epub 2015 Sep 9.
Reference Type
BACKGROUND
Debono M, Harrison RF, Chadarevian R, Gueroult C, Abitbol JL, Newell-Price J. Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3461-3469. doi: 10.1210/jc.2017-00823.
Reference Type
BACKGROUND
Lombardo G, Enache D, Gianotti L, Schatzberg AF, Young AH, Pariante CM, Mondelli V. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis. Psychoneuroendocrinology. 2019 Dec;110:104420. doi: 10.1016/j.psyneuen.2019.104420. Epub 2019 Aug 23.
Reference Type
BACKGROUND
Sigalas PD, Garg H, Watson S, McAllister-Williams RH, Ferrier IN. Metyrapone in treatment-resistant depression. Ther Adv Psychopharmacol. 2012 Aug;2(4):139-49. doi: 10.1177/2045125312436597.
Reference Type
BACKGROUND
Athimulam S, Delivanis D, Thomas M, Young WF, Khosla S, Drake MT, Bancos I. The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers. J Clin Endocrinol Metab. 2020 May 1;105(5):1469-77. doi: 10.1210/clinem/dgaa120.
Reference Type
BACKGROUND
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. Epub 2020 May 6. No abstract available.
Reference Type
BACKGROUND
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. No abstract available.
Reference Type
BACKGROUND
Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010 May 15;1(2):36-47. doi: 10.4239/wjd.v1.i2.36.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05J102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
NCT00677313
COMPLETED
NA
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
NCT03080181
COMPLETED
PHASE4
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
NCT07104812
RECRUITING
PHASE2
Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma
NCT01382420
UNKNOWN
NA
Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment
NCT00699530
WITHDRAWN
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
NCT06701838
NOT_YET_RECRUITING
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
NCT01504555
UNKNOWN
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
NCT03817840
COMPLETED
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
NCT02697734
COMPLETED
PHASE3
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
NCT03364803
RECRUITING
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00936741
COMPLETED
PHASE3
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
NCT07045935
RECRUITING
PHASE4
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
NCT03277690
COMPLETED
PHASE3
Effects of Mindfulness Therapy in Patients With Acromegaly and Cushing
NCT04420000
COMPLETED
NA
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
NCT04374721
UNKNOWN
NA
Effect of Genistein in Women With Metabolic Syndrome
NCT00541710
COMPLETED
PHASE2/PHASE3
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
NCT02860923
COMPLETED
PHASE3
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
NCT04743960
COMPLETED
NA
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
NCT02180217
COMPLETED
PHASE3
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
NCT02889224
COMPLETED
NA
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
NCT00744224
COMPLETED
NA
Do Antidepressants Induce Metabolic Syndromes METADAP Study
NCT00526383
COMPLETED
NA
The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity
NCT01384279
COMPLETED
NA
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
NCT05663749
COMPLETED
PHASE4
Effects of Herbal Products on Metabolism and Hunger
NCT00198952
COMPLETED
NA